MedTrace Logo

Apixaban Drug Utilization Study In Stroke Prevention In Atrial Fibrillation (Spaf)

NCT03441633 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 51690

Last updated 2023-06-09

Study results available
· View outcomes & findings →

Summary

Apixaban is a direct anticoagulant, which inhibits the factor Xa. Its clinical efficiency in prevention of stroke and systemic embolism in adult patients with NVAF (non/valvular atrial fibrillation) was demonstrated as well as has shown better safety profile compared with warfarin. A Drug Utilization study will evaluate whether this drug has been used in accordance with the approved indication and recommendations described in the summary of product characteristics (SmPC) and estimate possible misuse or overuse apixaban.

Conditions

Interventions

DRUG

apixaban

current or new medication

DRUG

dabigatran

current or new medication

DRUG

VKA

current or new medication

DRUG

rivaroxaban

current or new medication

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-18
Primary Completion
2017-03-08
Completion
2017-03-08

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03441633 on ClinicalTrials.gov